Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

Centre, University College London. "These data indicate BIBF 1120 may have a potential role in delaying disease progression in patients with ovarian cancer who had previously responded to chemotherapy."(11)

Because angiogenesis plays a pivotal role in the growth of solid tumors,(13) BIBF 1120 is currently being investigated in a number of cancer types including advanced NSCLC. The LUME-Lung Phase III clinical trial program is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC. Approximately 2,600 patients will be enrolled, making this one of the largest Phase III study programs in this NSCLC patient population to date.

About Lung Cancer

Lung cancer is the world's most common cancer and kills more people than any other cancer.(3,14) In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).(18)

About Ovarian Cancer

According to the 2008 World Health Organization World Cancer Report, as of 2002, ovarian cancer was ranked as the 6th most common cancer in women. Additionally, approximately 204,000 new cases were diagnosed worldwide and 125,000 women died from the disease in 2002.(14) The ACS estimates that about 21,650 new cases of ovarian cancer were diagnosed in the United States (U.S.) during 2008. Only forty-five percent of women with ovarian cancer are still alive at least five years after diagnosis in the U.S.(19)

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- MedSolutions ( www.medsolutions.com ), a leading provider ... new studies highlighting the dangers of excess radiation ... tests. ,, "When used properly, CT imaging ... Gregg Allen, M.D., chief medical officer of MedSolutions. ... that stricter quality control measures are necessary to ...
(Date:12/16/2009)... -- HDT Engineered Technologies (HDT), a leader in ... principal subcontractor for the mechanical development of the ... anthropromorphic arm technology that will give patients improved, ... including a sense of touch. ,, As ... (DARPA) Revolutionizing Prosthetics 2009 (RP2009) project, the MPL ...
(Date:12/16/2009)... Ethicon, Inc., a Johnson & Johnson ... worldwide leader in surgical care, and Acclarent, Inc., ... designing, developing and commercializing devices that address conditions ... announced a definitive merger agreement whereby Ethicon will ... $785 million net of estimated cash on hand ...
Breaking Medicine Technology:MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4Availity Provides Real Time Access to WellCare 55281 1Availity Provides Real Time Access to WellCare 55281 2Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 55277 1Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 55277 2Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 55277 3Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 1Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 2Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 3Just in Time for Allergy Season ZYRTEC 28R 29 Provides New Solutions for Adults and Children 55272 4
... Studies TAX 323 and TAX 324 Published, ... results of two clinical studies demonstrating that,Taxotere(R) (docetaxel) ... for induction therapy, significantly improved overall,survival (OS) in ... head and neck (SCCHN) are published in the ...
... sleep apnea and sleep behavior,disorders, ROCHESTER, Minn., ... diagnosing and treating patients with a,variety of sleep ... at CHEST 2007, the annual meeting of the ... 20-25. The following are,brief summaries of select presentations., ...
Other Medicine Technology:Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 4
(Date:12/17/2009)... NSRTSM is found very effective in the alleviation of symptoms ... chronic fatigue and a wide array of skin conditions. ... holistic therapy including over 50 branded BioVeda Health and Wellness ... ... December 16, 2009 -- BioVeda Health and Wellness Centers, LLC. ...
(Date:12/16/2009)... If proposed health care legislation is enacted, it ... system. Approximately 18.4 million Californians and 161 million ... employer-based insurance for their health care coverage. ... legislation entail specific requirements for employer-based insurance. ... firms that currently comply with most new standards, ...
(Date:12/16/2009)... Dec. 16 New Enterprise Associates, Inc. ... announced that one of its portfolio companies, Acclarent, ... be acquired by Ethicon, Inc., a Johnson & ... $785 million (net of estimated cash on hand ... dedicated to designing, developing and commercializing devices that ...
(Date:12/16/2009)... Allscripts (Nasdaq: MDRX ) announced today that ... three and six months ended November 30, 2009 ... 11, 2010. Allscripts management will host a conference ... and other information at 8:30 AM Eastern Standard ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter earnings ...
(Date:12/16/2009)... is long-term goal, researchers say , , WEDNESDAY, Dec. ... to predict whether a patient will suffer a second ... "This is an important new tool because studies have ... after a first stroke are more likely to die ... General Hospital and Harvard Medical School, said in an ...
Breaking Medicine News(10 mins):Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 5Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Stroke Tool May Predict Early Recurrence 2
... NEW YORK, Feb 4 March of Dimes New ... serve as the,official Celebrity Chairman for March for Babies(SM) in ... the March of Dimes,premier fundraising event that benefits all babies-those ... and thrive., "I,m proud to be partnering with March ...
... fiscal year 2009, if enacted, would spell disaster for ... to respond to the HIV/AIDS epidemic in the United ... federal support for research at the National Institutes of ... Disease Control and Prevention (CDC), and vital health care ...
... Unreasonable, Most Unrealistic, of,Entire White House Tenure, ... of the Bush Administration,s FY 2009 budget plan, ... is unreasonable from the,standpoint of seniors, Medicare-financed nursing ... economic conditions in states across,the nation -- which ...
... ... Technology, CALGARY, ... global leader in high-quality, low-cost digital,radiography systems, today announced that it ... for four of its X-Series,digital radiography systems. IDC was chosen for ...
... Exemptions Increase Costs, WASHINGTON, Feb. 4 ... statement in response to,the Federal Trade Commission,s (FTC) ... individual and corporate health care providers in,Puerto Rico ... "This latest comment from the FTC highlights the ...
... Dr. Sheela Sathyanarayana Fails to Disclose Political Activism, ... publication of a report from the American Academy ... Center for Individual Freedom,(CFIF) today criticized the report ... science. In addition to the report "conveniently" omitting,well-known ...
Other Medicine News:Health News:Eli Manning Teams Up with March of Dimes in New York City 2Health News:2009 Bush budget a disaster for HIV/AIDS 2Health News:Bush Budget Represents 'Double Whammy' Hit on U.S. Seniors' Medicare-Financed Nursing Facility Care 2Health News:Orthopaedic Clinic of Daytona Beach Chooses IDC for Transition to Digital X-ray 2Health News:Conflict of Interest in American Academy of Pediatrics Report 2Health News:Conflict of Interest in American Academy of Pediatrics Report 3
Lyophilized, tri-level assayed human serum-based control, Low, intermediate and high levels, Lot-specific target values provided, Suitable for use with RIA, EIA and chemiluminescent,methodo...
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
... Follicle-stimulating hormone (FSH) is a ... pituitary gland. Like hCG, LH and ... a noncovalently-linked dimer consisting of alpha- ... are stimulated by gonadotropin-releasing hormone (GnRH) ...
... Class II Direct to High Res SSP kits provide ... single tray. Locus specific typing on a single tray ... Straight from genomic DNA to high resolution results, ... level typing with a single tray , Unique reaction ...
Medicine Products: